Macrophage migration inhibitory factor (MIF) is a potent pro-inflammatory cytokine that also counter-regulates glucocorticoid action. We investigated whether immunoneutralization of MIF could reverse established experimental crescentic glomerulonephritis and if this treatment could modulate endogenous glucocorticoid levels. Accelerated anti-GBM glomerulonephritis was induced in six littermate pairs of rats. Once crescentic disease was established on day 7, one animal in each pair was given a daily injection of neutralizing anti-MIF antibody (Ab) or irrelevant isotype control Ab for 14 days and then killed on day 21. In addition, a group of 6 animals was killed on day 7 of disease without any treatment. Animals receiving the control Ab exhibited a rapidly progressive glomerulonephritis with severe renal injury (proteinuria), loss of renal function (creatinine clearance), anemia, and marked histologic damage (including glomerular crescent formation), compared with animals killed on day 7 without treatment. In contrast, anti-MIF Ab treatment partially reversed the disease by restoring normal renal function and reducing histological damage compared with untreated animals killed on day 7 (p < 0.05). Interestingly, anti-MIF Ab treatment also prevented severe anemia (p < 0.05). Reversal of disease was associated with a significant reduction in leukocyte infiltration and activation and renal interleukin-1 (IL-1) production. Importantly, anti-MIF Ab treatment caused a significant increase in endogenous serum corticosterone levels, which correlated with the reversal of disease parameters. In conclusion, this study has demonstrated that blocking MIW activity can partially reverse established crescentic glomerulonephritis and suggests that MIF operates by both enhancing the cellular immune response and suppressing the endogenous anti-inflammatory glucocorticoid response.
Introduction
Macrophage migration inhibitory factor (MIF) was first described over 30 years ago as a product of activated T cells that inhibited the migration of macrophages in vitro and promoted macrophage accumulation in the skin delayed-type hypersensitivity reaction (1, 2) . The recent cloning and characterization of MIF has led to the recognition that this molecule occupies a pivotal position in regulating the inflammatory and immune responses (3) . The use of neutralizing antibodies (Ab) has confirmed the central role of MIF in the cutaneous response to tuberculin (4) . In addition, a requirement for MIF in primary T cell activation and T cell-dependent immunoglobulin production has been demonstrated in vitro and in vivo (5) . An unexpected property of MIF was the discovery that it acts as a counterregulator for glucocorticoid action. Injection of dexamethasone into mice causes an increase in serum MIF levels, while the addition of recombinant MIF overcomes dexamethasone-mediated inhibition of lipopolysaccharide-induced cytokine secretion in vitro (6) . In addition, administration of recombinant MIF can overcome dexamethasone inhibition of lethal endotoxemia in mice (6) . Consistent with its role as a regulator of glucocorticoids, preformed MIF is present at high levels within secretory granules of corticotrophic cells of the anterior pituitary (7) . Indeed, MIF is widely expressed in most normal tissues (8, 9) .
We have recently described constitutive MIF expression by intrinsic glomerular and tubular epithelial cells of the rat kidney. There is a marked increase in both renal and systemic MIF production during the development of crescentic glomerulonephritis in the rat, which is dependent upon tumor necrosis factor-a (TNF-a) activity (10, 11) . Treatment of rats with a neutralizing anti-MIF antibody (Ab) significantly inhibits the induction of this aggressive model of kidney disease, providing the first evidence that MIF participates in the pathogenesis of immunologically induced disease (12) . This inhibition of disease induction was associated with a suppression of blood monocyte recruitment and subsequent macrophage-mediated tissue injury. This finding has opened up two important questions. First Circulating levels of rat IgG reactive with rabbit immunoglobulin were quantitated by a sandwich ELISA, as previously described (24) . Deposition of immune reactants within the kidney was assessed by direct immunofluorescence. Tissues were snap frozen in liquid nitrogen and 4-,um cryostat sections were stained with FITCconjugated polyclonal antibodies to rat IgG, C3, or rabbit IgG. Semi-quantitation of rabbit IgG, rat IgG, and C3 deposition was determined in tissue sections using an antibody titration method (22, 24) . Sections from each tissue were incubated with serial 2-fold dilutions of each antibody. Slides were blinded and the antibody dilution at which staining became undetectable was scored.
Immunohistochemistry Three-layer immunoperoxidase staining was performed on cryostat sections of tissues fixed in 2% paraformaldehyde-lysine-periodate (PLP) as previously described (22) . Briefly, sections were preincubated with 10% fetal calf serum (FCS) and 10% normal goat serum in PBS for 20 min, drained, and labeled with a mouse mAb for 60 min, washed (X 3) in PBS, and endogenous peroxidase inactivated by incubation in 0.3% H202 in methanol. Sections were then washed in PBS, incubated with peroxidase-conjugated goat antimouse IgG, washed in PBS, and incubated with mouse peroxidase anti-peroxidase complexes and developed with 3,3-diaminobenzidine to produce a brown color. Sections were counterstained with PAS minus hematoxylin.
In Situ Hybridization In situ hybridization was performed on 4-gm paraffin sections of formalin-fixed tissue using a microwave-based protocol (10, 25) . After dewaxing, sections were treated with 2 x 5 min microwave oven heating in 0.01 M sodium citrate, pH 6.0, at 2450 MHz and 800 W, incubated with 0.2 M HCI for 15 min, followed by 1% Triton X-100 for 15 min, and then digested for 20 min with 10 ,g/ml proteinase-K at 37°C (Boehringer Mannheim). Sections were then washed in 2 X SSC, prehybridized, and then hybridized with 0.3 ng/,ul digoxigenin-labeled sense or anti-sense MIF cRNA probe overnight at 42°C in a hybridization buffer containing 50% deionized formamide, 4 X SSC, 1 mg/ml salmon sperm DNA, and 1 mg/ml yeast tRNA. Sections were washed finally in 0.1 X SSC at 42°C and the hybridized probe detected using alkaline phosphatase-conjugated sheep anti-digoxigenin F(ab) fragments and color development with NBT/X-phosphate. Sections were counterstained with PAS minus hematoxylin. Hybridization with the MIF cRNA sense probe gave no signal.
Quantitation of Tissue Staining
A standard semi-quantitative method was used to score the glomerular and tubulointerstitial infiltrates as previously described (10, 22, 24) . Cells labeled by each mAb or by the MIF cRNA probe were counted in high-power fields (X40) of 20 consecutive glomerular cross sections for each animal and expressed as the number of labeled cells per glomerular cross section (gcs). Glomerular staining with the anti-IL-13 Ab was graded on a scale of (0) no staining; (1) <25% stained; (2) 25-50% stained; (3) >50% of the gcs stained. To assess interstitial staining, cortical areas were selected at random. The number of labeled interstitial cells was counted in 20 consecutive high-power fields by means of a 0.02 mm2 graticule fitted in the eyepiece of the microscope and expressed as cells per mm2. These fields progressed from the outer to inner cortex, avoiding only large vessels and glomerular and immediate periglomerular areas. For each tissue, the same area was examined in serial sections labeled with different Ab. No adjustment of the interstitial cell count was made for tubules or the luminal space. Tubular expression of MIF and IL-113 was scored in at least 1000 cortical tubules in high-power fields as previously described ( 12) . Data are expressed as the mean for six animals ± SEM. All counting was performed on blinded slides. Glomerular MIF Production Glomeruli were isolated by differential sieving in which a half kidney from each animal was placed in RPMI 1640 medium with 5% FCS, diced finely, gently pressed through a 250-,um wire mesh and poured through a 106-,um and then a 75-,um wire mesh. Glomeruli remaining on the top of the 75-,tm mesh were washed extensively with RPMI/5% FCS and collected. Isolated glomeruli were >95% pure as assessed by phasecontrast microscopy. Glomeruli were cultured at 3000 glomeruli/ml in RPMI 1640/5% FCS in 5% CO2 at 370C for 24 
Results
Renal Function and Histological Damage All animals on day 7 of anti-GBM disease exhibited significant proteinuria (p < 0.001 vs. normal), a significant increase in serum creatinine levels (p < 0.01 versus normal), and a decrease in creatinine clearance (not significant) (Fig. 1) . Animals killed on day 7 of disease with no treatment exhibited significant glomerular and tubular lesions, including glomerular crescent formation (Fig. 2) This is consistent with previous studies in which animals treated with saline or an irrelevant control antibody developed a very similar, rapid progressive disease (8, 12, 26) . In contrast, those animals treated with the anti-MIF Ab showed a partial reversal of established crescentic glomerulonephritis. In particular, serum levels of urea and creatinine returned to the normal range and animals exhibited hyperfiltration (increased creatinine clearance) (Fig. 1) . Furthermore, there was a significant reduction in glomerular hypercellularity, segmental lesions, and crescent formation in animals treatment with anti-MIF Ab compared with animals killed on day 7 without any treatment (Fig. 2) . (Fig. 3a) . Severe anemia was evident in control Ab-treated animals on day 21 , with a significant reduction in red blood cell counts and blood hemoglobin levels. In contrast, animals treated with the anti-MIF Ab prevented the development of anemia (Fig. 3b, c increase in interstitial leukocytes oIn day 7 of anti-GBM disease (p < 0.01). Macrophages were the main infiltrating cell type in the glomerulus, while a mixed macrophage and T cell infiltrate was seen in the interstitium (Fig. 4) . A further increase in macrophage and T cell infiltration, including T cell activation (interleukin-2 receptor expression ), was seen in those animals treated with the control Ab over days 7 to 21. This increase inl leukocyte infiltratioIn and activation was abrogated by anti-MIF Ab treatmlent (Fig. 4) and 6). In contrast, no further increase in renal MIF expression was seen in anti-MIF Ab-treated animals (Figs. 5D and 6). As a second method to evaluate MIF production, secretion of MIF by isolated glomeruli cultured for 24 hr was quantitated. There was no increase in the level of MIF secretion by glomeruli at day 7 of disease compared with glomeruli from normal animals (1894 + 150 versus 1955 + 169 pg/ml, respectively, p = N.S.). However, animals receiving the irrelevanit control Ab over days 7 to 21 showed a significant increase in glomerular MIF secretion (4249 + 977 pg/ml, p < 0.05 versus untreated day 7 disease), which was suppressed by anti-MIF Ab treatment (1571 + 177 pg/ml, p < 0.05 versus control Ab treated). Interleukin-1 (IL-1) is another pro-inflammatory cytokine known to participate in leukocyte recruitment in this disease model (22, 27) . Therefore, we examined the effect of anti-MIF Ab treatment on renal IL-1X3 production. There was a significant increase in the glomerular IL-1 3 staining score on day 7 of the disease compared with normal rat kidney (p < 0.05). There was a further increase in the glomerular IL-1(3 score and a significant increase in the percentage of cortical tubules expressing IL-1,3 over days 7 to 21 with control Ab treatment, but this was suppressed by anti-MIF Ab treatment (Fig. 7) . plasma corticosterone levels in all animals on day 21 (n = 12) with various disease parameters using the Pearson single correlation coefficient ( Table 1 ). The number of glomerular and tubular cells expressing MIF mRNA gave a highly significant negative correlation with corticosterone levels. The number of interstitial macrophages and immune-activated cells (IL-2R+), but not glomerular macrophage infiltration, gave a negative correlation with corticosterone levels. In addition, parameters of renal injury and renal function gave a significant negative correlation with corticosterone levels (Table 1) .
Discussion
While a variety of intervention strategies have been shown to be successful in preventing the induction of the immune response that leads to the development of immune-mediated diseases, it has proven far more difficult to halt or even partially reverse progressive tissue injury once it is established. Indeed, this is the crucial test of any new therapeutic strategy, as patients invariably present to the clinician after their disease is already established. The present study has, therefore, extended previous results by demonstrating that antibody-based neutralization of MIF activity can halt and even partially reverse established crescentic glomerulonephritis in the rat.
The ability of anti-MIF Ab treatment to inhibit established disease can be attributed to two distinct mechanisms. First, MIF is known to participate directly in the cellular immune response (4, 5) . Consistent with a previous study (12) , the cellular immune response in this disease was suppressed by anti-MIF Ab treatment as demonstrated by inhibition of the skin DTH response, a reduced macrophage and T cell infiltrate within the kidney, and a reduction in immune activation (IL-2R expression) of the mononuclear cell infiltrate. The inhibition of leukocyte infiltration may be due in part to inhibition of local IL-i 3 production since this cytokine is known to promote renal leukocyte accumulation through induction of molecules such as intercellular adhesion molecule-1 and monocyte chemoattractant protein-i (27) (28) (29) . In contrast to the cellular immune response, anti-MIF Ab treatment had no effect upon the secondary antibody response.
The second mechanism by which neutralization of MIF activity suppressed this disease is through counter-regulation of glucocorticoid production. Whereas administration of recombinant MIF has been shown to inhibit dexamethasone mediated suppression of lethal endotoxaemia in mice (6) , the relationship between endogenous production of MIF and glucocorticoids in immune-mediated disease is unknown. There is an increase in both circulating MIF levels and local renal MIF production during the development of rat anti-GBM disease (10, 11) . The current study showed that increased MIF production during the early phase of disease development was associated with a suppression of serum corticosterone levels. In addition, neutralization of MIF activity caused an increase in corticosterone levels to above that seen in normal animals. These findings suggest that endogenous MIF may act to regulate glucocorticoid levels in immune-mediated glomerulonephritis. Furthermore, the increase in corticosterone levels seen with anti-MIF Ab treatment may have contributed to the suppression of the cellular immune response. Indeed, a sharp rise in endogenous glucocorticoid levels has been shown to play a crucial role in the resolution of acute paralyzing injury in rat experimental allergic encephalomyelitis (EAE) (30). Also, the basal level of endogenous serum corticosterone has been shown to be an important factor in the susceptibility of Lewis, but not PVG.RTIC, rats to the induction of EAE (31) . The finding that serum corticosterone did not rise above normal levels in control Abtreated anti-GBM disease probably reflects the very aggressive nature of this disease model, which progresses rapidly towards end-stage renal failure.
Erythropoietin is produced by interstitial cells within the kidney (32, 33) . Anemia is a common complication of renal failure caused by a reduction in erythropoietin production in the injured renal interstitium (34) . In the current study, anti-MIF Ab treatment of established anti-GBM disease prevented the development of severe anemia, demonstrating that neutralizing MIF activity provides substantial protection against interstitial injury during disease progression.
In summary, this study has demonstrated that blocking MIF activity can partially reverse established crescentic glomerulonephritis. While MIF has been identified previously to act as a counter-regulator of glucocorticoid action (6) , the present data suggest that in vivo MIF may also influence glucocorticoid levels, providing an additional level of regulation on the ensuing inflammatory and immune responses.
